Memorial Sloan-Kettering
Despite Precision Oncology Drug Approval Boom, 'Success' Isn't So Easily Won, Researchers Admit
Premium
In a Cancer Discovery paper, MSK researchers charted impressive growth in FDA-approved precision oncology drugs and eligibility but acknowledged major limitations in the field.
MSK Team Finds Immunotherapy May Lessen Visceral Tumor Risk After Lynch Syndrome-Linked Cancer
Premium
In a retrospective study, investigators found that immunotherapy-treated patients had lower rates of visceral tumors after immune checkpoint inhibitors than those on chemo.
Sophia Genetics, Memorial Sloan Kettering, AstraZeneca Partner to Broaden Cancer Sequencing Access
The companies aim to create a decentralized global network for genomic cancer testing, including underserved regions where access remains limited.
Myriad Genetics, Memorial Sloan Kettering Partner to Study MRD Testing in Breast Cancer
The collaborators will evaluate the use of Myriad's MRD platform in predicting response to CDK4/6 inhibitors and in a chemotherapy neoadjuvant setting.
Ovarian Cancer Patients Without BRCA Mutations Benefit From Lynparza, Imfinzi Plus Standard of Care
Premium
Data presented at ASCO suggests that patients with BRCA-wild type tumors could benefit from a regimen comprising the PARP and checkpoint inhibitors added to chemo and Avastin.